To the Editor In their study, Chan et al1 report the effectiveness of omalizumab in treating severe pediatric atopic dermatitis, with significant clinical benefit. While these encouraging results suggest that omalizumab may be a viable treatment option for this patient group, the Editorial2 on this study succinctly raised the issue of cost-effectiveness because the cost of omalizumab administration could amount to greater than $100 000 per year. Thus, there needs to be a strong rationale for using omalizumab in favor of other treatment options.
Park J. Comparing the Roles of Omalizumab and Ultraviolet Therapy in Treating Severe Pediatric Atopic Dermatitis. JAMA Pediatr. Published online June 15, 2020. doi:10.1001/jamapediatrics.2020.0960
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: